Abstract Subject Categories
The subject categories for abstract submission are listed below. You must select the most appropriate category for your abstract and insert its corresponding number in the box on the abstract form. Please be aware that the Symposium Abstract Review Committee may re-categorize your abstract if doing so is deemed appropriate. Unless noted otherwise, all abstract categories listed below are available for during regular and late breaking submission cycles.
Subject Categories List
- Adverse Effects of Cancer Treatment and Symptom Management
- Animal and ex vivo Models
- Artificial Intelligence, Computational Biology, and Systems Biology
- Behavioral and Population Science
- Breast Cancer Risk, Genetics, and Prevention
- Breast Cancer: Early Stage - HER2+
- Breast Cancer: Early Stage - Hormone Receptor Positive
- Breast Cancer: Early Stage - Other
- Breast Cancer: Early Stage - Triple Negative
- Breast Cancer: Metastatic - HER2+
- Breast Cancer: Metastatic - Hormone Receptor Positive
- Breast Cancer: Metastatic - Other
- Breast Cancer: Metastatic - Triple Negative
- Cancer Health Disparities
- Cancer Survivorship and Quality of Life
- Clinical Biomarkers, Translational Research, and Precision Medicine
- Clinical Case Studies (not available for late breaking abstracts)
- Drug Discovery, Design, and Delivery
- Experimental Therapeutics and Early Phase Trials
- Imaging / Early Detection
- Mechanisms of Resistance
- Molecular and Cell Tumor Biology
- Ongoing Clinical Trials (see rules below)
- Policy, Access to Care, Health Outcomes and Cancer Care Delivery
- Radiation Oncology
- Real-World Data and Real-World Evidence
- Tumor Microenvironment, Immunology, and Angiogenesis
ONGOING CLINICAL TRIALS
This category is for work that is ongoing. It is to inform and inspire, and/or to invite the collaboration of others. It is to not to discuss the trial results, either preliminary or formally completed - presentations with this type of information should be submitted as regular abstracts.
Trials with any type of focus may be submitted (treatment, prevention, biomarker endpoints, supportive care, educational, and psychosocial endpoints).
What should be presented in the abstract and eventually in the poster is:
- A brief background discussion
- Trial design
- Eligibility criteria
- Specific aims
- Statistical methods
- Present accrual and target accrual
- Contact information for people with a specific interest in the trial
Again, inclusion of preliminary or final trial results will disqualify an abstract in this category and is not allowed on the poster, though information on accrual to date or confirmation of feasibility is acceptable. Poster presentations in the Ongoing Clinical Trials category are not subject to SABCS pre-publication and embargo policies.
Clinical Case Studies
This category is for clinical cases or clinical vignettes to present interesting patient cases. Only submissions with a clinical trainee as the corresponding author will be considered for presentation (example - medical student, resident, fellow). This category is only available during the regular abstract submission cycle.
Late Breaking Abstracts
Late breaking submissions will open on August 21 and
close on September 30. A placeholder abstract for late-breaking abstracts is not required during the general call for abstracts. Only paradigm shifting basic science discovery, or
translational or clinical research of relevance to patients will be considered.
Please note that, due to program schedule considerations, most if not all late
acceptances will be programmed as posters.